Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sionna Therapeutics, Inc. (SION : NSDQ)

• Company Description    Sionna Therapeutics Inc. is a clinical-stage biopharmaceutical company by developing novel medicines that normalize the function of the CFTR protein. Sionna Therapeutics Inc. is based in BOSTON. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $7.18 Daily Weekly Monthly 20 Day Moving Average: 2,806,439 shares Shares Outstanding: 45.21 (millions) Market Capitalization: $324.62 (millions) Beta: 0.89 52 Week High: $54.97 52 Week Low: $4.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 59.56% 60.27% 12 Week -80.06% -80.48% Year To Date -82.55% -84.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 21 HICKORY DRIVE SUITE 500 - WALTHAM,MA 02451 USA ph: 617-819-2020 fax: - ir@sionnatx.com http://www.sionnatx.com

• General Corporate Information    Officers Michael Cloonan - Chief Executive Officer and President Paul Clancy - Chairman Elena Ridloff - Chief Financial Officer Bruce Booth - Director H. Edward Fleming - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 829401108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 45.21 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $324.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.22 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -60.98% vs. Previous Quarter: -10.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -32.94 03/31/26 - -27.31 12/31/25 - -22.87 ROA 06/30/26 - -31.08 03/31/26 - -25.88 12/31/25 - -21.71 Current Ratio 06/30/26 - 20.05 03/31/26 - 22.60 12/31/25 - 20.61 Quick Ratio 06/30/26 - 20.05 03/31/26 - 22.60 12/31/25 - 20.61 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 5.89 03/31/26 - 6.38 12/31/25 - 6.88 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©